Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT plus ambrisentan for psychological outcomes and quality of life in pulmonary arterial hypertension
ChiCTR2600118415Phase 2Not yet recruiting
- Sponsor
- Handan First Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ambrisentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Handan First Hospital. Primary endpoints: Anxiety level at 3 months, Depressive level at 3 months and 6 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ChiCTR2600118415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118415.